Bookedited by Daniel W. Lee, Nirali N. Shah.
Contents:
Introduction
When to refer a patient for CAR-T cell therapy
Optimizing the apheresis product
CAR T cells: cell processing laboratory considerations
Peri-CAR-T cell management
Management of cytokine release syndrome
Special considerations for ICU management of patients receiving CAR therapy
Neurotoxicities after CAR-T cell immunotherapy
Hematologic and non-CRS toxicities
Response assessment and post-CAR-T cell therapy management
Relapse management and role for consolidative hematopoietic stem cell transplantation following CAR-T cell therapy
Promising chimeric antigen receptors for non-B cell hematological malignancies, pediatric solid tumors, and carcinomas
CAR T cell therapy for CNS malignancies
CAR 2.0: the next generation of synthetic receptor-based cellular therapy for cancer.